clinical trial · NCT07709897
A Clinical Trial of HRS5580 for Injection Combined With Palonosetron Hydrochloride for the Prevention of Postoperative Nausea and Vomiting
Fujian Shengdi Pharmaceutical Co., Ltd.·phase2·not yet recruiting·n = 260
Prevention of Postoperative Nausea and VomitingHRS5580 for injection combined with palonosetron hydrochloride;HRS5580 for injection combined with palonosetron hydrochlorideHRS5580 for injection combined with palonosetron hydrochlorideHRS5580 for injection blank preparation combined with palonosetron hydrochloride
brief summary
The study is being conducted to evaluate the efficacy of HRS5580 for injection combined with palonosetron hydrochloride in the prevention of postoperative nausea and vomiting, and to explore the effective dose of HRS5580 for injection combined with palonosetron hydrochloride for the prevention of postoperative nausea and vomiting.
started
Jul 1, 2026
primary completion
Dec 1, 2026
completion
Dec 1, 2026
last updated
Jul 17, 2026
official title
A Multicenter, Randomized, Dose-finding, Positive-controlled, Double-blind, Double-dummy Phase II Clinical Trial to Evaluate the Efficacy and Safety of HRS5580 for Injection Combined With Palonosetron Hydrochloride in the Prevention of Postoperative Nausea and Vomiting
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol